Division of Medicinal Chemistry, Graduate School of Pharmaceutical Sciences, Duquesne University, 600 Forbes Avenue, Pittsburgh, PA 15282, USA.
Bioorg Med Chem. 2013 Feb 15;21(4):891-902. doi: 10.1016/j.bmc.2012.12.010. Epub 2012 Dec 20.
A series of fourteen N(4)-(substituted phenyl)-N(4)-alkyl/desalkyl-9H-pyrimido[4,5-b]indole-2,4-diamines was synthesized as potential microtubule targeting agents. The synthesis involved a Fisher indole cyclization of 2-amino-6-hydrazinylpyrimidin-4(3H)-one with cyclohexanone, followed by oxidation, chlorination and displacement with appropriate anilines. Compounds 6, 14 and 15 had low nanomolar potency against MDA-MB-435 tumor cells and depolymerized microtubules. Compound 6 additionally had nanomolar GI(50) values against 57 of the NCI 60-tumor panel cell lines. Mechanistic studies showed that 6 inhibited tubulin polymerization and [(3)H]colchicine binding to tubulin. The most potent compounds were all effective in cells expressing P-glycoprotein or the βIII isotype of tubulin, which have been associated with clinical drug resistance. Modeling studies provided the potential interactions of 6, 14 and 15 within the colchicine site.
合成了一系列 14 种 N(4)-(取代苯基)-N(4)-烷基/去烷基-9H-嘧啶并[4,5-b]吲哚-2,4-二胺,作为潜在的微管靶向剂。该合成涉及 2-氨基-6-肼基嘧啶-4(3H)-酮与环己酮的 Fisher 吲哚环化反应,然后进行氧化、氯化和与适当苯胺的取代。化合物 6、14 和 15 对 MDA-MB-435 肿瘤细胞具有低纳摩尔效力,并使微管解聚。化合物 6 对 NCI 60 肿瘤面板细胞系中的 57 种具有纳摩尔 GI(50)值。机制研究表明,化合物 6 抑制微管蛋白聚合和 [(3)H]秋水仙碱与微管蛋白的结合。最有效的化合物在表达 P-糖蛋白或微管 βIII 同工型的细胞中均有效,这些同工型与临床药物耐药性有关。建模研究提供了化合物 6、14 和 15 在秋水仙碱结合位点的潜在相互作用。